News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Borealis Foods (BRLS) has announced a delay in filing its Form 10-Q for the quarter ended June 30, 2026, citing the need for more time to prepare and review financial statements. The company expects to file within five days and does not anticipate significant …
Maxim Group has reiterated its Buy rating for Palisade Bio (PALI.US) and maintained its target price at $8. This indicates continued confidence from the firm in the company's prospects.
Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz have filed an amended Schedule 13G/A, reporting 0.0% beneficial ownership of Palisade Bio (PALI) common stock. The group indicates they hold 0.00 shares, representing 0.0% of the class, with no sole …
Latham & Watkins LLP advised Zentalis Pharmaceuticals, Inc. in its recent underwritten public offering, which is expected to generate approximately US$80.5 million in gross proceeds. The offering involved 23,000,000 shares of common stock at US$3.50 per share, with an option for underwriters to purchase …
Ameriprise Financial, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) revealing a 5.8% ownership stake in Personalis, Inc. common stock as of June 30, 2026. This ownership includes shared voting power over 6,054,599 shares and shared dispositive power over 6,086,315 shares. Ameriprise …
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A for Personalis, Inc. (PSNL). The filing indicates that as of June 30, 2026, the group beneficially owned 4,000,000 shares of Personalis common stock, representing 3.82% …
Zentalis Pharmaceuticals has raised approximately USD 80.5 million through an equity offering to fund the late-stage development and pre-commercial activities for its oral WEE1 inhibitor, azenosertib. The drug is being evaluated for Cyclin E1-positive platinum-resistant ovarian cancer, with Phase II data expected by year-end …
Palisade Bio, Inc. (NASDAQ:PALI) has received a consensus "Buy" recommendation from brokerages, with an average one-year target price of $9.00. The article details recent analyst ratings, including several "buy" and "strong-buy" recommendations, alongside some changes to "hold" and "sell" ratings. It also highlights recent …
Zentalis Pharmaceuticals (ZNTL [https://seekingalpha.com/symbol/ZNTL]) announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20619418-zentalis-pharmaceuticals-announces-pricing-of-underwritten-public-offering] of 23M shares of its common stock at a public offering price of $3.50 per share. Gross proceeds from the offering are expected to be approximately $80.5M before deducting underwriting discounts, …
(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage oncology company, priced a public offering of 23 million shares at $3.50 per share. The total gross proceeds from the offering are expected to be $80.5 million, and the company plans to use the net proceeds …
Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) has announced the pricing of an underwritten public offering of 23 million shares of common stock at $3.50 per share, aiming to raise approximately $80.5 million in gross proceeds. The offering is expected to close on August 17, 2026, with …
Barclays PLC has filed an amended Schedule 13G, disclosing a 3.17% beneficial ownership stake in Zentalis Pharmaceuticals Inc. (ZNTL), totaling 2,263,328 shares as of June 30, 2026. This filing indicates that Barclays now holds 5 percent or less of the class. The ownership includes …
Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shares dropped 6.5% after announcing an underwritten public stock offering, which will include common stock and pre-funded warrants. The company plans to use the proceeds to fund clinical trials, preclinical studies, regulatory filings, and manufacturing for its oncology programs, particularly …
Soleus Capital Master Fund, L.P. and its affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of 13,063,687 shares of Palisade Bio, Inc. (PALI) common stock. This represents a 7.5% stake in the company, based on 174,270,558 shares outstanding as …
Materialise (NASDAQ:MTLS) stock recently moved above its 50-day moving average, trading at $6.80 compared to an average of $6.73. Analyst sentiment is mixed, with an average "Hold" rating and a $10.00 price target, though Wall Street Zen downgraded it from "strong buy" to "buy." …
American Acquisition Corp. A (AEXA), a Cayman Islands blank check company, reported Q2 2026 net income of $2.8 million and $5.7 million for the first half, primarily from interest earned on its Trust Account investments. The company holds $355.1 million in total assets, with …
Oppenheimer analyst Leland Gershell reiterated a Buy rating on Palisade Bio (PALI) with an $8.00 price target. The company currently holds a Strong Buy consensus rating with an average price target of $7.00. Despite reporting a wider GAAP net loss in its latest quarter, …
HC Wainwright analysts have reduced their Q3 2026 earnings per share estimates for Zentalis Pharmaceuticals (NASDAQ:ZNTL) to a loss of $0.63, down from $0.57. Despite this, the firm maintained a "Buy" rating and a $10 price target for the stock. Zentalis reported a Q2 …
Dimensional Fund Advisors LP increased its holdings in Personalis, Inc. (PSNL) by 8.4% in the first quarter, now owning 1.07 million shares valued at approximately $6.8 million. Despite this, insiders have sold a significant amount of stock, and the company has a consensus "Hold" …
(RTTNews) - Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss and provided a business update. Company Profile Palisade Bio develops prodrugs for patients living with inflammatory and fibrotic …
Personalis (PSNL) recently reported Q2 2026 results with increased sales but wider losses, leading to a reassessment of its stock by investors. Despite strong recent share price performance, the stock is currently trading slightly above analyst targets, with a narrative fair value suggesting it …
Palisade Bio (NASDAQ:PALI) announced plans to initiate a Phase 2 clinical trial for its drug candidate PALI-2108 in ulcerative colitis during the second half of 2026, with results expected in late 2027. The company also intends to file an investigational new drug application for …
Palisade Bio (NASDAQ:PALI) announced its quarterly earnings, reporting a loss of $0.05 per share, which met analyst expectations, and revenue of $0.50 million. The stock saw a slight dip, trading down 0.5% to $2.10, while analysts maintain an overall "Buy" rating with a target …
Palisade Bio (NASDAQ: PALI) reported a Q2 2026 net loss of $10.6 million, significantly wider than the $2.8 million loss in Q2 2025, primarily due to increased R&D expenses for its lead candidate, PALI-2108. Despite the widening loss, the company's EPS of $(0.05) met …
PALISADE BIO, INC. (PALI) reported second-quarter 2026 financial results with $0.5 million in revenue and a net loss of $10.6 million, or $(0.05) diluted EPS. This marks an increase in revenue compared to the year-ago quarter, though the net loss widened. The company also …
Search by ticker symbol or company name and select a result to open its chart.